T. Rowe Price Associates
RPTP

T. Rowe Price Associates’s RAPTOR PHARMACEUTICAL CORP COM STK (DE) RPTP Stock Holding History

T. Rowe Price Associates’s Portfolio RPTP Stock Details RPTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,700
Closed -$159K – 2615
2016
Q3 		$159K Sell
17,700
-24,600
-58% -$175K ﹤0.01% 2383
2016
Q2 		$227K Hold
42,300
– – ﹤0.01% 2279
2016
Q1 		$195K Buy
42,300
+19,400
+85% +$78K ﹤0.01% 2297
2015
Q4 		$119K Sell
22,900
-10,700
-32% -$62.1K ﹤0.01% 2398
2015
Q3 		$203K Sell
33,600
-6,600
-16% -$80.9K ﹤0.01% 2288
2015
Q2 		$635K Buy
40,200
+6,800
+20% +$82.6K ﹤0.01% 1900
2015
Q1 		$363K Buy
33,400
+6,400
+24% +$65.3K ﹤0.01% 2106
2014
Q4 		$284K Hold
27,000
– – ﹤0.01% 2201
2014
Q3 		$259K Hold
27,000
– – ﹤0.01% 2217
2014
Q2 		$312K Sell
27,000
-4,500
-14% -$41K ﹤0.01% 2163
2014
Q1 		$315K Buy
31,500
+8,400
+36% +$121K ﹤0.01% 2134
2013
Q4 		$301K Buy
+23,100
New +$318K ﹤0.01% 2140

T. Rowe Price Associates's RPTP Position: Q4 2016 in Review

T. Rowe Price Associates sold out of RAPTOR PHARMACEUTICAL CORP COM STK (DE) (RPTP) in Q4 2016, closing a stake of 17,700 shares — an estimated $159K sold.

T. Rowe Price Associates first reported a position in RPTP in Q4 2013 and held it in 12 quarters. The position peaked at $635K in Q2 2015. 0 funds tracked by Wall St. Rank hold RPTP as of Q4 2016.

  • T. Rowe Price Associates reported no remaining RAPTOR PHARMACEUTICAL CORP COM STK (DE) position as of Q4 2016 after selling out during the quarter.
  • T. Rowe Price Associates sold 17,700 RAPTOR PHARMACEUTICAL CORP COM STK (DE) shares in Q4 2016, an estimated $159K.
  • T. Rowe Price Associates first reported a position in RAPTOR PHARMACEUTICAL CORP COM STK (DE) in Q4 2013 and held it in 12 quarters.
  • T. Rowe Price Associates's RAPTOR PHARMACEUTICAL CORP COM STK (DE) position peaked at $635K in Q2 2015.
  • 0 funds tracked by Wall St. Rank held RAPTOR PHARMACEUTICAL CORP COM STK (DE) as of Q4 2016.

Based on T. Rowe Price Associates's 13F filing for Q4 2016, filed 14 Feb 2017.